SCNI Stock Slides As Scinai Refocuses On NanoAb Platform

Scinai Immunotherapeutics Ltd. surged as investors reacted to its most impactful positive news, and stocks have been trading up by 34.94 percent

Live Update At 08:32:41 EDT: On Monday, September 14, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 34.94%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SCNI has been trading like a textbook downtrend on the daily chart. After a post‑reverse‑split spike from roughly $0.29 on 2026/08/20 to the low $3s by 2026/08/24–2026/08/26, Scinai Immunotherapeutics Ltd. has bled lower almost every trading day. The stock closed near $3.22 on 2026/08/21, then faded into the mid‑$2s and is now in the high‑$1 range, with a recent close around $1.66–$1.71. That is a steep drawdown and tells traders the hot money has been leaving.

Intraday, SCNI’s 5‑minute chart shows classic gap‑and‑fade price action. Strong early moves from about $2.01 to above $3.20 around the 04:50–05:00 window get sold into, with lower highs and steady pressure afterward. For short‑term traders, that intraday structure screams “trade the pops, not the drops.”

Fundamentals back up the story of a small, high‑risk biotech. Scinai Immunotherapeutics reported about $1.31M in revenue with a price‑to‑sales ratio near 0.63 and price‑to‑book around 0.34, reflecting a market that heavily discounts its equity. Returns on assets and equity are deep in the red, and leverage is meaningful. For SCNI traders, this is a capital‑hungry story where price moves are likely to track news flow and sentiment more than steady cash generation.

Why Traders Are Watching SCNI’s Strategic Pivot

SCNI is now making a clear strategic turn that traders need to understand. Scinai Immunotherapeutics is walking away from its option and license agreements with PinCell for the PC111 program. That decision kills one path of external optionality, and any long‑term bull thesis anchored on PC111 needs to be rewritten. When a micro‑cap biotech like SCNI exits a program, the market often reads it as “less pipeline, more risk.”

But the other half of the story matters just as much. Scinai Immunotherapeutics is not cutting R&D; it is reallocating that capital into its in‑house NanoAb antibody platform. SCNI is telling the market it wants tighter control over its science and economics. For traders, this is a portfolio reshaping move, not a collapse in operations.

At the same time, SCNI is leaning harder into its CDMO business, Scinai Biopharma Services. That unit, while still small, is designed to bring in service revenue that does not depend on binary clinical catalysts. If Scinai Immunotherapeutics grows this CDMO arm, it can smooth cash flow and extend runway, a critical factor for a company with negative returns and a modest asset base.

The continued collaboration with the Max Planck Society and University Medical Center Göttingen supports the NanoAb focus. Those names carry scientific credibility, which can help sentiment even before hard data arrives. For active traders, the key is that SCNI has moved from a broader, partnership‑driven pipeline toward a more concentrated bet on NanoAb plus CDMO revenue. That sort of pivot often fuels sharp, news‑driven spikes both ways.

Conclusion

SCNI is trading like a high‑beta, news‑sensitive biotech, and this latest move by Scinai Immunotherapeutics underscores why. Terminating the PinCell PC111 option and license agreements removes one potential future asset, and the market rarely rewards lost optionality right away. The recent slide from above $3 to under $2 lines up with a chart that already favored sellers, so traders need to respect the trend.

At the same time, SCNI is not standing still. Scinai Immunotherapeutics is refocusing its R&D war chest on its own NanoAb antibody platform, while pushing its Scinai Biopharma Services CDMO unit as a complementary revenue stream. The ongoing collaborations with the Max Planck Society and University Medical Center Göttingen give the NanoAb program a scientific backbone that many tiny biotechs lack.

For short‑term traders, SCNI remains a classic catalyst and chart setup: low price, beaten‑down trend, and a fresh strategic narrative. Any headlines about NanoAb progress, CDMO contracts, or updated guidance can light a fire under the stock, in either direction. As Tim Sykes loves to say, “Patterns repeat because human nature doesn’t change.” As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”. SCNI’s job now is to show the market that this pivot is more than a press release while disciplined traders wait for clean, high‑volume setups to trade—not to hope.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks